6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Jun 2025
- Reporting date
- 12 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,805 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 401-425 of 1,000 matching filings.
Per page
25
Current page
17
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 12 Jun 2025
- Reporting date
- 12 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 11 Jun 2025
- Reporting date
- 11 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 11 Jun 2025
- Reporting date
- 11 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 10 Jun 2025
- Reporting date
- 10 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 09 Jun 2025
- Reporting date
- 09 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 06 Jun 2025
- Reporting date
- 06 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 05 Jun 2025
- Reporting date
- 05 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK - SECOND TRANCHE OF SHARE BUYBACK PROGRAMME
- Filing date
- 04 Jun 2025
- Reporting date
- 04 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 04 Jun 2025
- Reporting date
- 04 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 03 Jun 2025
- Reporting date
- 03 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 02 Jun 2025
- Reporting date
- 02 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 02 Jun 2025
- Reporting date
- 02 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
LINERIXIBAT FILE ACCEPTED FOR REVIEW BY US FDA
- Filing date
- 02 Jun 2025
- Reporting date
- 02 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 02 Jun 2025
- Reporting date
- 02 Jun 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SD
File 001-15170
SPECIALIZED DISCLOSURE REPORT
- Filing date
- 30 May 2025
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 30 May 2025
- Reporting date
- 30 May 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 29 May 2025
- Reporting date
- 29 May 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK STOPS PHASE 3 TRIAL ON CUTIS FOR EFFICACY
- Filing date
- 28 May 2025
- Reporting date
- 28 May 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 28 May 2025
- Reporting date
- 28 May 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 27 May 2025
- Reporting date
- 27 May 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
POSITIVE CHMP OPINION ON BLENREP IN EU
- Filing date
- 23 May 2025
- Reporting date
- 23 May 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FDA APPROVES NUCALA COPD INDICATION
- Filing date
- 23 May 2025
- Reporting date
- 23 May 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 23 May 2025
- Reporting date
- 23 May 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 22 May 2025
- Reporting date
- 22 May 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing